---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-056585"
form_type: "8-K"
ticker: "TARA"
cik: "0001359931"
company_name: "Protara Therapeutics, Inc."
filed_at: "2021-11-04T23:59:59+00:00"
generated_at: "2026-06-28T12:44:47.299991+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Protara Therapeutics reports Q3 2021 net loss of $10.8M; FDA clears IND for TARA-002 in NMIBC

## Summary
- Net loss $10.8M ($0.96/sh) vs $8.0M ($1.26/sh) in Q3 2020; R&D expense $4.1M (up from $2.8M), G&A $6.7M (up from $5.3M).
- Cash, equivalents and marketable debt securities $138.4M as of Sept 30, 2021.
- FDA cleared IND for TARA-002 in non-muscle invasive bladder cancer; Phase 1 trial start planned by year-end 2021.
- Hired Mary Grendell (ex-Intercept Pharmaceuticals) as General Counsel; completed GMP comparability for TARA-002.

## SEC filing metadata
- accession: 0001213900-21-056585
- form_type: 8-K
- ticker: TARA
- cik: 0001359931
- company_name: Protara Therapeutics, Inc.
- filed_at: 2021-11-04T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1359931/000121390021056585/0001213900-21-056585-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1359931/000121390021056585/ea149909-8k_protara.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-056585
- JSON: https://secwatch.observer/filing/0001213900-21-056585.json
- Plain text: https://secwatch.observer/filing/0001213900-21-056585.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.